Edwards Lifesciences (NYSE:EW) Sees Large Volume Increase

Edwards Lifesciences Co. (NYSE:EW) shares saw an uptick in trading volume on Friday . 1,601,121 shares were traded during mid-day trading, a decline of 57% from the previous session’s volume of 3,683,971 shares.The stock last traded at $60.88 and had previously closed at $59.70.

Analyst Ratings Changes

A number of equities research analysts have commented on EW shares. Stifel Nicolaus decreased their price objective on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a report on Thursday. Piper Sandler dropped their price objective on shares of Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating for the company in a research report on Thursday. Deutsche Bank Aktiengesellschaft cut their target price on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday. JPMorgan Chase & Co. lowered shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $105.00 to $72.00 in a report on Thursday. Finally, Evercore ISI lowered their target price on shares of Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating for the company in a report on Thursday. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $82.10.

Edwards Lifesciences Trading Up 4.0 %

The stock has a market cap of $37.43 billion, a price-to-earnings ratio of 27.14, a PEG ratio of 3.18 and a beta of 1.11. The business’s 50 day simple moving average is $88.51 and its 200 day simple moving average is $86.93. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 24.55%. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter last year, the firm posted $0.66 EPS. The company’s quarterly revenue was up 6.7% on a year-over-year basis. On average, research analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the sale, the vice president now owns 173,849 shares in the company, valued at approximately $14,639,824.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $14,639,824.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 7,250 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $85.80, for a total transaction of $622,050.00. Following the transaction, the chief financial officer now owns 19,074 shares of the company’s stock, valued at $1,636,549.20. The disclosure for this sale can be found here. Insiders have sold a total of 81,099 shares of company stock worth $7,003,553 in the last quarter. Corporate insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of EW. Park Avenue Securities LLC raised its stake in Edwards Lifesciences by 0.5% during the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after buying an additional 108 shares during the last quarter. Martin Capital Advisors LLP boosted its position in shares of Edwards Lifesciences by 0.5% during the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after purchasing an additional 128 shares in the last quarter. City State Bank grew its stake in Edwards Lifesciences by 16.5% during the second quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after purchasing an additional 130 shares during the period. Chapin Davis Inc. increased its holdings in Edwards Lifesciences by 1.7% in the first quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock worth $817,000 after purchasing an additional 140 shares in the last quarter. Finally, Johnson Financial Group Inc. lifted its stake in Edwards Lifesciences by 23.0% in the fourth quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock valued at $59,000 after buying an additional 144 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.